CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

UBS Upgrades Medpace Holdings to Neutral From Sell, Adjusts Price Target to $673 From $405

Positive
AI Analysis

Summary

UBS upgraded Medpace Holdings from Sell to Neutral and raised its price target to $673 from $405, reflecting improved investor sentiment toward the contract research organization.

Importance:3/10
Sentiment:
0.60
analyst_upgradeprice_target_increaserating_change
Related Companies

Read the original article

Published by yahoo_finance on September 30, 2026 1:06 PM

Read Original